N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety
- PMID:25580916
- DOI: 10.1097/WNF.0000000000000063
N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety
Abstract
Objectives: According to the proposed interference of N-acetylcysteine (NAC) with pathophysiologic processes of autistic disorders (ADs), we aimed to assess the effectiveness and safety of NAC as an adjunct to risperidone in the treatment of ADs in a randomized, double-blind, clinical trial.
Methods: The participants were referred outpatients between 4 and 12 years of age with the diagnosis of ADs and a score of more than 12 on Aberrant Behavior Checklist-Community (ABC-C) Irritability subscale score. The participants were randomized into 2 groups. One group received risperidone plus NAC, and the other group received risperidone plus placebo. The dose of risperidone was titrated between 1 and 2.0 mg/d, and the dose of NAC was 600 to 900 mg/d. The main outcome was mean decrease in the ABC-C irritability subscale score from baseline at 5 and 10 weeks. Changes in other subscales were considered as secondary outcome measures.
Results: Forty patients completed the 10-week trial. Baseline characteristics including age, sex and body weight, as well as baseline scores in 5 subscales did not demonstrate statistically significant difference between the 2 groups. Repeated-measures analysis showed significant effect for time × treatment interaction in irritability (P = 0.01) and hyperactivity/noncompliance (P = 0.02) subscales. By week 10, the NAC group showed significantly more reduction in irritability (P = 0.02) and hyperactivity/noncompliance (P = 0.01) subscales scores.
Conclusions: N-acetylcysteine can be considered as an adjuvant therapy for ADs with beneficial therapeutic outcomes.
Similar articles
- l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.Hajizadeh-Zaker R, Ghajar A, Mesgarpour B, Afarideh M, Mohammadi MR, Akhondzadeh S.Hajizadeh-Zaker R, et al.J Child Adolesc Psychopharmacol. 2018 Feb;28(1):74-81. doi: 10.1089/cap.2017.0026. Epub 2017 Oct 13.J Child Adolesc Psychopharmacol. 2018.PMID:29027815Clinical Trial.
- Simvastatin as an Adjunctive Therapy to Risperidone in Treatment of Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Moazen-Zadeh E, Shirzad F, Karkhaneh-Yousefi MA, Khezri R, Mohammadi MR, Akhondzadeh S.Moazen-Zadeh E, et al.J Child Adolesc Psychopharmacol. 2018 Feb;28(1):82-89. doi: 10.1089/cap.2017.0055. Epub 2017 Jul 18.J Child Adolesc Psychopharmacol. 2018.PMID:28719227Clinical Trial.
- Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder.Rezaei V, Mohammadi MR, Ghanizadeh A, Sahraian A, Tabrizi M, Rezazadeh SA, Akhondzadeh S.Rezaei V, et al.Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1269-72. doi: 10.1016/j.pnpbp.2010.07.005. Epub 2010 Jul 14.Prog Neuropsychopharmacol Biol Psychiatry. 2010.PMID:20637249Clinical Trial.
- Placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: A review.Chen AT, Chibnall JT, Nasrallah HA.Chen AT, et al.Ann Clin Psychiatry. 2016 Aug;28(3):190-6.Ann Clin Psychiatry. 2016.PMID:27490835Review.
- Role of risperidone in children with autism spectrum disorder.Chavez B, Chavez-Brown M, Rey JA.Chavez B, et al.Ann Pharmacother. 2006 May;40(5):909-16. doi: 10.1345/aph.1G389. Epub 2006 Mar 7.Ann Pharmacother. 2006.PMID:16684811Review.
Cited by
- The Use of Complementary Alternative Medicine in Children and Adolescents with Autism Spectrum Disorder.DeFilippis M.DeFilippis M.Psychopharmacol Bull. 2018 Jan 15;48(1):40-63.Psychopharmacol Bull. 2018.PMID:29382959Free PMC article.Review.
- A Narrative Review about Autism Spectrum Disorders and Exclusion of Gluten and Casein from the Diet.González-Domenech PJ, Diaz-Atienza F, Gutiérrez-Rojas L, Fernández-Soto ML, González-Domenech CM.González-Domenech PJ, et al.Nutrients. 2022 Apr 25;14(9):1797. doi: 10.3390/nu14091797.Nutrients. 2022.PMID:35565765Free PMC article.Review.
- Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD).Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D.Iffland M, et al.Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2.Cochrane Database Syst Rev. 2023.PMID:37811711Free PMC article.Review.
- Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis.D'Alò GL, De Crescenzo F, Amato L, Cruciani F, Davoli M, Fulceri F, Minozzi S, Mitrova Z, Morgano GP, Nardocci F, Saulle R, Schünemann HJ, Scattoni ML; ISACA Guideline Working Group.D'Alò GL, et al.Health Qual Life Outcomes. 2021 Jan 25;19(1):33. doi: 10.1186/s12955-021-01669-0.Health Qual Life Outcomes. 2021.PMID:33494757Free PMC article.
- Use of N-Acetylcysteine in Psychiatric Conditions among Children and Adolescents: A Scoping Review.Naveed S, Amray A, Waqas A, Chaudhary AM, Azeem MW.Naveed S, et al.Cureus. 2017 Nov 29;9(11):e1888. doi: 10.7759/cureus.1888.Cureus. 2017.PMID:29392100Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources